Sec. 227. Frequency of reporting for certain devices. 
Sec. 228. Inspections by accredited persons. 
Sec. 229. Study of nosocomial infections relating to medical devices. 
Sec. 230. Report by the Food and Drug Administration regarding labeling in-
formation on the relationship between the use of indoor tan-
ning devices and development of skin cancer or other skin dam-
age. 
TITLE III—PEDIATRIC MEDICAL DEVICE SAFETY AND 
IMPROVEMENT ACT OF 2007 
Sec. 301. Short title. 
Sec. 302. Tracking pediatric device approvals. 
Sec. 303. Modification to humanitarian device exemption. 
Sec. 304. Encouraging pediatric medical device research. 
Sec. 305. Demonstration grants for improving pediatric device availability. 
Sec. 306. Amendments to office of pediatric therapeutics and pediatric advisory 
committee. 
Sec. 307. Postmarket surveillance. 
TITLE IV—PEDIATRIC RESEARCH EQUITY ACT OF 2007 
Sec. 401. Short title. 
Sec. 402. Reauthorization of Pediatric Research Equity Act. 
Sec. 403. Establishment of internal committee. 
Sec. 404. Government Accountability Office report. 
TITLE V—BEST PHARMACEUTICALS FOR CHILDREN ACT OF 2007 
Sec. 501. Short title. 
Sec. 502. Reauthorization of Best Pharmaceuticals for Children Act. 
Sec. 503. Training of pediatric pharmacologists. 
TITLE VI—REAGAN-UDALL FOUNDATION 
Sec. 601. The Reagan-Udall Foundation for the Food and Drug Administra-
tion. 
Sec. 602. Office of the Chief Scientist. 
Sec. 603. Critical path public-private partnerships. 
TITLE VII—CONFLICTS OF INTEREST 
Sec. 701. Conflicts of interest. 
TITLE VIII—CLINICAL TRIAL DATABASES 
Sec. 801. Expanded clinical trial registry data bank. 
TITLE IX—ENHANCED AUTHORITIES REGARDING POSTMARKET 
SAFETY OF DRUGS 
Subtitle A—Postmarket Studies and Surveillance 
Sec. 901. Postmarket studies and clinical trials regarding human drugs; risk 
evaluation and mitigation strategies. 
Sec. 902. Enforcement. 
Sec. 903. No effect on withdrawal or suspension of approval. 
Sec. 904. Benefit-risk assessments. 
Sec. 905. Active postmarket risk identification and analysis.
Sec. 906. Statement for inclusion in direct-to-consumer advertisements of 
drugs. 
Sec. 907. No effect on veterinary medicine. 
Sec. 908. Authorization of appropriations. 
Sec. 909. Effective date and applicability. 
Subtitle B—Other Provisions to Ensure Drug Safety and Surveillance 
Sec. 911. Clinical trial guidance for antibiotic drugs. 
Sec. 912. Prohibition against food to which drugs or biological products have 
been added. 
Sec. 913. Assuring pharmaceutical safety. 
Sec. 914. Citizen petitions and petitions for stay of agency action. 
Sec. 915. Postmarket drug safety information for patients and providers. 
Sec. 916. Action package for approval. 
Sec. 917. Risk communication. 
Sec. 918. Referral to advisory committee. 
Sec. 919. Response to the institute of medicine. 
Sec. 920. Database for authorized generic drugs. 
Sec. 921. Adverse drug reaction reports and postmarket safety. 
TITLE X—FOOD SAFETY 
Sec. 1001. Findings. 
Sec. 1002. Ensuring the safety of pet food. 
Sec. 1003. Ensuring efficient and effective communications during a recall. 
Sec. 1004. State and Federal Cooperation. 
Sec. 1005. Reportable Food Registry. 
Sec. 1006. Enhanced aquaculture and seafood inspection. 
Sec. 1007. Consultation regarding genetically engineered seafood products. 
Sec. 1008. Sense of Congress. 
Sec. 1009. Annual report to Congress. 
Sec. 1010. Publication of annual reports. 
Sec. 1011. Rule of construction. 
TITLE XI—OTHER PROVISIONS 
Subtitle A—In General 
Sec. 1101. Policy on the review and clearance of scientific articles published by 
FDA employees. 
Sec. 1102. Priority review to encourage treatments for tropical diseases. 
Sec. 1103. Improving genetic test safety and quality. 
Sec. 1104. NIH Technical amendments. 
Sec. 1105. Severability clause. 
Subtitle B—Antibiotic Access and Innovation 
Sec. 1111. Identification 
of 
clinically 
susceptible 
concentrations 
of 
antimicrobials. 
Sec. 1112. Orphan antibiotic drugs. 
Sec. 1113. Exclusivity of certain drugs containing single enantiomers. 
Sec. 1114. Report.
TITLE I—PRESCRIPTION DRUG 
USER FEE AMENDMENTS OF 2007 
SEC. 101. SHORT TITLE; REFERENCES IN TITLE; FINDING. 
(a) SHORT TITLE.—This title may be cited as the 
‘‘Prescription Drug User Fee Amendments of 2007’’. 
(b) REFERENCES IN TITLE.—Except as otherwise 
specified, amendments made by this title to a section or 
other provision of law are amendments to such section or 
other provision of the Federal Food, Drug, and Cosmetic 
Act (21 U.S.C. 301 et seq.). 
(c) FINDING.—The Congress finds that the fees au-
thorized by the amendments made in this title will be dedi-
cated toward expediting the drug development process and 
the process for the review of human drug applications, in-
cluding postmarket drug safety activities, as set forth in 
the goals identified for purposes of part 2 of subchapter 
C of chapter VII of the Federal Food, Drug, and Cosmetic 
Act, in the letters from the Secretary of Health and 
Human Services to the Chairman of the Committee on 
Health, Education, Labor, and Pensions of the Senate and 
the Chairman of the Committee on Energy and Commerce 
of the House of Representatives, as set forth in the Con-
gressional Record. 
SEC. 102. DEFINITIONS. 
Section 735 (21 U.S.C. 379g) is amended—
(1) in the matter before paragraph (1), by 
striking ‘‘For purposes of this subchapter’’ and in-
serting ‘‘For purposes of this part’’; 
(2) in paragraph (1)— 
(A) in subparagraph (A), by striking 
‘‘505(b)(1),’’ and inserting ‘‘505(b), or’’; 
(B) by striking subparagraph (B); 
(C) by redesignating subparagraph (C) as 
subparagraph (B); and 
(D) in the matter following subparagraph 
(B), as so redesignated, by striking ‘‘subpara-
graph (C)’’ and inserting ‘‘subparagraph (B)’’; 
(3) in paragraph (3)(C)— 
(A) by striking ‘‘505(j)(7)(A)’’ and insert-
ing ‘‘505(j)(7)(A) (not including the discon-
tinued section of such list)’’; and 
(B) by inserting before the period ‘‘(not in-
cluding the discontinued section of such list)’’; 
(4) in paragraph (4), by inserting before the pe-
riod at the end the following: ‘‘(such as capsules, 
tablets, or lyophilized products before reconstitu-
tion)’’; 
(5) by amending paragraph (6)(F) to read as 
follows:
‘‘(F) Postmarket safety activities with re-
spect to drugs approved under human drug ap-
plications or supplements, including the fol-
lowing activities: 
‘‘(i) Collecting, developing, and re-
viewing safety information on approved 
drugs, including adverse event reports. 
‘‘(ii) Developing and using improved 
adverse-event data-collection systems, in-
cluding information technology systems. 
‘‘(iii) Developing and using improved 
analytical tools to assess potential safety 
problems, including access to external data 
bases. 
‘‘(iv) Implementing and enforcing sec-
tion 505(o) (relating to postapproval stud-
ies and clinical trials and labeling changes) 
and section 505(p) (relating to risk evalua-
tion and mitigation strategies). 
‘‘(v) Carrying out section 505(k)(5) 
(relating to adverse event reports and 
postmarket safety activities).’’; 
(6) in paragraph (8)—
(A) by striking ‘‘April of the preceding fis-
cal year’’ and inserting ‘‘October of the pre-
ceding fiscal year’’; and 
(B) by striking ‘‘April 1997’’ and inserting 
‘‘October 1996’’; 
(7) by redesignating paragraph (9) as para-
graph (11); and 
(8) by inserting after paragraph (8) the fol-
lowing paragraphs: 
‘‘(9) The term ‘person’ includes an affiliate 
thereof. 
‘‘(10) The term ‘active’, with respect to a com-
mercial investigational new drug application, means 
such an application to which information was sub-
mitted during the relevant period.’’. 
SEC. 103. AUTHORITY TO ASSESS AND USE DRUG FEES. 
(a) TYPES OF FEES.—Section 736(a) (21 U.S.C. 
379h(a)) is amended— 
(1) in the matter preceding paragraph (1), by 
striking ‘‘2003’’ and inserting ‘‘2008’’; 
(2) in paragraph (1)— 
(A) in subparagraph (D)— 
(i) in the heading, by inserting ‘‘OR 
WITHDRAWN BEFORE FILING’’ after ‘‘RE-
FUSED FOR FILING’’; and
(ii) by inserting before the period at 
the end the following: ‘‘or withdrawn with-
out a waiver before filing’’; 
(B) by redesignating subparagraphs (E) 
and (F) as subparagraphs (F) and (G), respec-
tively; and 
(C) by inserting after subparagraph (D) 
the following: 
‘‘(E) 
FEES
FOR
APPLICATIONS
PRE-
VIOUSLY REFUSED FOR FILING OR WITHDRAWN 
BEFORE FILING.—A human drug application or 
supplement that was submitted but was refused 
for filing, or was withdrawn before being ac-
cepted or refused for filing, shall be subject to 
the full fee under subparagraph (A) upon being 
resubmitted or filed over protest, unless the fee 
is waived or reduced under subsection (d).’’; 
and 
(3) in paragraph (2)— 
(A) in subparagraph (A), by striking ‘‘sub-
paragraph (B)’’ and inserting ‘‘subparagraphs 
(B) and (C)’’; and 
(B) by adding at the end the following: 
‘‘(C) SPECIAL RULES FOR POSITRON EMIS-
SION TOMOGRAPHY DRUGS.—
‘‘(i) IN
GENERAL.—Except as pro-
vided in clause (ii), each person who is 
named as the applicant in an approved 
human drug application for a positron 
emission tomography drug shall be subject 
under subparagraph (A) to one-sixth of an 
annual establishment fee with respect to 
each such establishment identified in the 
application as producing positron emission 
tomography drugs under the approved ap-
plication. 
‘‘(ii) EXCEPTION FROM ANNUAL ES-
TABLISHMENT FEE.—Each person who is 
named as the applicant in an application 
described in clause (i) shall not be assessed 
an annual establishment fee for a fiscal 
year if the person certifies to the Sec-
retary, at a time specified by the Secretary 
and using procedures specified by the Sec-
retary, that— 
‘‘(I) the person is a not-for-profit 
medical center that has only 1 estab-
lishment 
for 
the 
production 
of 
positron emission tomography drugs; 
and
‘‘(II) at least 95 percent of the 
total number of doses of each positron 
emission tomography drug produced 
by such establishment during such fis-
cal year will be used within the med-
ical center. 
‘‘(iii) DEFINITION.—For purposes of 
this subparagraph, the term ‘positron 
emission tomography drug’ has the mean-
ing given to the term ‘compounded 
positron emission tomography drug’ in sec-
tion 201(ii), except that paragraph (1)(B) 
of such section shall not apply.’’. 
(b) FEE REVENUE AMOUNTS.—Section 736(b) (21 
U.S.C. 379h(b)) is amended to read as follows: 
‘‘(b) FEE REVENUE AMOUNTS.— 
‘‘(1) IN GENERAL.—For each of the fiscal years 
2008 through 2012, fees under subsection (a) shall, 
except as provided in subsections (c), (d), (f), and 
(g), be established to generate a total revenue 
amount under such subsection that is equal to the 
sum of— 
‘‘(A) $392,783,000; and
‘‘(B) an amount equal to the modified 
workload adjustment factor for fiscal year 2007 
(as determined under paragraph (3)). 
‘‘(2) TYPES
OF
FEES.—Of the total revenue 
amount determined for a fiscal year under para-
graph (1)— 
‘‘(A) one-third shall be derived from fees 
under subsection (a)(1) (relating to human 
drug applications and supplements); 
‘‘(B) one-third shall be derived from fees 
under subsection (a)(2) (relating to prescription 
drug establishments); and 
‘‘(C) one-third shall be derived from fees 
under subsection (a)(3) (relating to prescription 
drug products). 
‘‘(3) MODIFIED WORKLOAD ADJUSTMENT FAC-
TOR
FOR
FISCAL
YEAR 2007.—For purposes of 
paragraph (1)(B), the Secretary shall determine the 
modified workload adjustment factor by determining 
the dollar amount that results from applying the 
methodology that was in effect under subsection 
(c)(2) for fiscal year 2007 to the amount 
$354,893,000, except that, with respect to the por-
tion of such determination that is based on the 
change in the total number of commercial investiga-
tional new drug applications, the Secretary shall 
count the number of such applications that were ac-
tive during the most recent 12-month period for 
which data on such submissions is available. 
‘‘(4) ADDITIONAL FEE REVENUES FOR DRUG 
SAFETY.— 
‘‘(A) IN GENERAL.—For each of the fiscal 
years 2008 through 2012, paragraph (1)(A) 
shall be applied by substituting the amount de-
termined 
under 
subparagraph 
(B) 
for 
‘$392,783,000’. 
‘‘(B) AMOUNT DETERMINED.—For each of 
the fiscal years 2008 through 2012, the amount 
determined under this subparagraph is the sum 
of— 
‘‘(i) $392,783,000; plus 
‘‘(ii)(I) 
for 
fiscal 
year 
2008, 
$25,000,000; 
‘‘(II) 
for 
fiscal 
year 
2009, 
$35,000,000; 
‘‘(III) 
for 
fiscal 
year 
2010, 
$45,000,000; 
‘‘(IV) 
for 
fiscal 
year 
2011, 
$55,000,000; and
‘‘(V) 
for 
fiscal 
year 
2012, 
$65,000,000.’’. 
(c) ADJUSTMENTS TO FEES.— 
(1) 
INFLATION
ADJUSTMENT.—Section 
736(c)(1) (21 U.S.C. 379h(c)(1)) is amended— 
(A) in the matter preceding subparagraph 
(A), by striking ‘‘The revenues established in 
subsection (b)’’ and inserting ‘‘For fiscal year 
2009 and subsequent fiscal years, the revenues 
established in subsection (b)’’; 
(B) in subparagraph (A), by striking ‘‘or’’ 
at the end; 
(C) in subparagraph (B), by striking the 
period at the end and inserting ‘‘, or’’; 
(D) by inserting after subparagraph (B) 
the following: 
‘‘(C) the average annual change in the 
cost, per full-time equivalent position of the 
Food and Drug Administration, of all personnel 
compensation and benefits paid with respect to 
such positions for the first 5 years of the pre-
ceding 6 fiscal years.’’; and 
(E) in the matter following subparagraph 
(C) (as added by subparagraph (D)), by strik-
ing ‘‘fiscal year 2003’’ and inserting ‘‘fiscal 
year 2008’’. 
(2) 
WORKLOAD
ADJUSTMENT.—Section 
736(c)(2) (21 U.S.C. 379h(c)(2)) is amended— 
(A) in the matter preceding subparagraph 
(A), by striking ‘‘Beginning with fiscal year 
2004,’’ and inserting ‘‘For fiscal year 2009 and 
subsequent fiscal years,’’; 
(B) in subparagraph (A), in the first sen-
tence— 
(i) by striking ‘‘human drug applica-
tions,’’ and inserting ‘‘human drug applica-
tions (adjusted for changes in review ac-
tivities, as described in the notice that the 
Secretary is required to publish in the 
Federal Register under this subpara-
graph),’’; 
(ii) by striking ‘‘commercial investiga-
tional new drug applications,’’; and 
(iii) by inserting before the period the 
following: ‘‘, and the change in the total 
number of active commercial investiga-
tional new drug applications (adjusted for 
changes in review activities, as so de-
scribed) during the most recent 12-month
period for which data on such submissions 
is available’’; 
(C) in subparagraph (B), by adding at the 
end the following: ‘‘Any adjustment for changes 
in review activities made in setting fees and rev-
enue amounts for fiscal year 2009 may not re-
sult in the total workload adjustment being 
more than 2 percentage points higher than it 
would have been in the absence of the adjust-
ment for changes in review activities.’’; and 
(D) by adding at the end the following: 
‘‘(C) The Secretary shall contract with an 
independent accounting firm to study the ad-
justment for changes in review activities applied 
in setting fees and revenue amounts for fiscal 
year 2009 and to make recommendations, if 
warranted, for future changes in the method-
ology for calculating the adjustment. After re-
view of the recommendations, the Secretary 
shall, if warranted, make appropriate changes 
to the methodology, and the changes shall be ef-
fective for each of the fiscal years 2010 through 
2012. The Secretary shall not make any adjust-
ment for changes in review activities for any
fiscal year after 2009 unless such study has 
been completed.’’. 
(3) RENT AND RENT-RELATED COST ADJUST-
MENT.—Section 736(c) (21 U.S.C. 379h(c)) is 
amended— 
(A) by redesignating paragraphs (3), (4), 
and (5) as paragraphs (4), (5), and (6), respec-
tively; and 
(B) by inserting after paragraph (2) the 
following: 
‘‘(3) RENT AND RENT-RELATED COST ADJUST-
MENT.—For fiscal year 2010 and each subsequent 
fiscal year, the Secretary shall, before making ad-
justments under paragraphs (1) and (2), decrease 
the fee revenue amount established in subsection (b) 
if actual costs paid for rent and rent-related ex-
penses for the preceding fiscal year are less than es-
timates made for such year in fiscal year 2006. Any 
reduction made under this paragraph shall not ex-
ceed the amount by which such costs fall below the 
estimates made in fiscal year 2006 for such fiscal 
year, and shall not exceed $11,721,000 for any fiscal 
year.’’. 
(4) FINAL YEAR ADJUSTMENT.—Paragraph (4) 
of section 736(c) (21 U.S.C. 379h(c)), as redesig-
nated by paragraph (3)(A), is amended to read as 
follows: 
‘‘(4) FINAL YEAR ADJUSTMENT.— 
‘‘(A) INCREASE IN FEES.—For fiscal year 
2012, the Secretary may, in addition to adjust-
ments under this paragraph and paragraphs 
(1), (2), and (3), further increase the fee reve-
nues and fees established in subsection (b) if 
such an adjustment is necessary to provide for 
not more than 3 months of operating reserves 
of carryover user fees for the process for the re-
view of human drug applications for the first 3 
months of fiscal year 2013. If such an adjust-
ment is necessary, the rationale for the amount 
of the increase shall be contained in the annual 
notice establishing fee revenues and fees for fis-
cal year 2012. If the Secretary has carryover 
balances for such process in excess of 3 months 
of such operating reserves, the adjustment 
under this subparagraph shall not be made. 
‘‘(B) DECREASE IN FEES.— 
‘‘(i) IN
GENERAL.—For fiscal year 
2012, the Secretary may, in addition to 
adjustments under this paragraph and 
paragraphs (1), (2), and (3), decrease the
fee revenues and fees established in sub-
section (b) by the amount determined in 
clause (ii), if, for fiscal year 2009 or 
2010— 
‘‘(I) the amount of the total ap-
propriations for the Food and Drug 
Administration for such fiscal year 
(excluding the amount of fees appro-
priated for such fiscal year) exceeds 
the amount of the total appropriations 
for the Food and Drug Administra-
tion for fiscal year 2008 (excluding 
the amount of fees appropriated for 
such fiscal year), adjusted as provided 
under paragraph (1); and 
‘‘(II) the amount of the total ap-
propriations expended for the process 
for the review of human drug applica-
tions at the Food and Drug Adminis-
tration for such fiscal year (excluding 
the amount of fees appropriated for 
such fiscal year) exceeds the amount 
of appropriations expended for the 
process for the review of human drug 
applications at the Food and Drug
Administration for fiscal year 2008 
(excluding the amount of fees appro-
priated for such fiscal year), adjusted 
as provided under paragraph (1). 
‘‘(ii) AMOUNT
OF
DECREASE.—The 
amount determined in this clause is the 
lesser of— 
‘‘(I) the amount equal to the sum 
of the amounts that, for each of fiscal 
years 2009 and 2010, is the lesser 
of— 
‘‘(aa) the excess amount de-
scribed in clause (i)(II) for such 
fiscal year; or 
‘‘(bb) the amount specified 
in subsection (b)(4)(B)(ii) for 
such fiscal year; or 
‘‘(II) $65,000,000. 
‘‘(iii) LIMITATIONS.— 
‘‘(I) FISCAL YEAR CONDITION.— 
In making the determination under 
clause (ii), an amount described in 
subclause (I) of such clause for fiscal 
year 2009 or 2010 shall be taken into
account only if subclauses (I) and (II) 
of clause (i) apply to such fiscal year. 
‘‘(II) RELATION
TO
SUBPARA-
GRAPH (A).—The Secretary shall limit 
any decrease under this paragraph if 
such a limitation is necessary to pro-
vide for the 3 months of operating re-
serves 
described 
in 
subparagraph 
(A).’’. 
(5) LIMIT.—Paragraph (5) of section 736(c) 
(21 U.S.C. 379h(c)), as redesignated by paragraph 
(3)(A), is amended by striking ‘‘2002’’ and inserting 
‘‘2007’’. 
(d) FEE WAIVER OR REDUCTION.—Section 736(d) 
(21 U.S.C. 379h(d)) is amended— 
(1) in paragraph (1), in the matter preceding 
subparagraph (A)— 
(A) by inserting after ‘‘The Secretary shall 
grant’’ the following: ‘‘to a person who is 
named as the applicant in a human drug appli-
cation’’; and 
(B) by inserting ‘‘to that person’’ after 
‘‘one or more fees assessed’’; 
(2) by redesignating paragraphs (2) and (3) as 
paragraphs (3) and (4), respectively;
(3) by inserting after paragraph (1) the fol-
lowing: 
‘‘(2) CONSIDERATIONS.—In determining wheth-
er to grant a waiver or reduction of a fee under 
paragraph (1), the Secretary shall consider only the 
circumstances and assets of the applicant involved 
and any affiliate of the applicant.’’; and 
(4) in paragraph (4) (as redesignated by para-
graph (2)), in subparagraph (A), by inserting before 
the period the following: ‘‘, and that does not have 
a drug product that has been approved under a 
human drug application and introduced or delivered 
for introduction into interstate commerce’’. 
(e) CREDITING AND AVAILABILITY OF FEES.— 
(1) AUTHORIZATION
OF
APPROPRIATIONS.— 
Section 736(g)(3) (21 U.S.C. 379h(g)(3)) is amend-
ed to read as follows: 
‘‘(3) AUTHORIZATION
OF
APPROPRIATIONS.— 
For each of the fiscal years 2008 through 2012, 
there is authorized to be appropriated for fees under 
this section an amount equal to the total revenue 
amount determined under subsection (b) for the fis-
cal year, as adjusted or otherwise affected under 
subsection (c) and paragraph (4) of this sub-
section.’’.
‘‘(A) The drug meets the public health re-
quirements contained in this Act as such re-
quirements are applied to requests for waivers 
for product and establishment fees. 
‘‘(B) The drug is owned or licensed and is 
marketed by a company that had less than 
$50,000,000 in gross worldwide revenue during 
the previous year. 
‘‘(2) EVIDENCE
OF
QUALIFICATION.—An ex-
emption under paragraph (1) applies with respect to 
a drug only if the applicant involved submits a cer-
tification that its gross annual revenues did not ex-
ceed $50,000,000 for the preceding 12 months be-
fore the exemption was requested.’’. 
(g) CONFORMING AMENDMENT.—Section 736(a) (21 
U.S.C. 379h(a)) is amended in paragraphs (1)(A)(i), 
(1)(A)(ii), (2)(A), and (3)(A) by striking ‘‘(c)(4)’’ each 
place such term appears and inserting ‘‘(c)(5)’’. 
(h) TECHNICAL AMENDMENT.— 
(1) 
AMENDMENT.—Section 
736(g)(1) 
(21 
U.S.C. 379h(g)(1)) is amended by striking the first 
sentence and inserting the following: ‘‘Fees author-
ized under subsection (a) shall be collected and 
available for obligation only to the extent and in the 
amount provided in advance in appropriations Acts.
Such fees are authorized to remain available until 
expended.’’. 
(2) EFFECTIVE
DATE.—Paragraph (1) shall 
take effect as if included in section 504 of the Pre-
scription Drug User Fee Amendments of 2002 
(Public Law 107–188; 116 Stat. 687). 
SEC. 104. FEES RELATING TO ADVISORY REVIEW OF PRE-
SCRIPTION-DRUG TELEVISION ADVERTISING. 
Part 2 of subchapter C of chapter VII (21 U.S.C. 
379g et seq.) is amended by adding after section 736 the 
following: 
‘‘SEC. 736A. FEES RELATING TO ADVISORY REVIEW OF PRE-
SCRIPTION-DRUG TELEVISION ADVERTISING. 
‘‘(a) TYPES OF DIRECT-TO-CONSUMER TELEVISION 
ADVERTISEMENT REVIEW FEES.—Beginning in fiscal 
year 2008, the Secretary shall assess and collect fees in 
accordance with this section as follows: 
‘‘(1) ADVISORY REVIEW FEE.— 
‘‘(A) IN GENERAL.—With respect to a pro-
posed direct-to-consumer television advertise-
ment (referred to in this section as a ‘DTC ad-
vertisement’), each person that on or after Oc-
tober 1, 2007, submits such an advertisement 
for advisory review by the Secretary prior to its 
initial public dissemination shall, except as pro-
vided in subparagraph (B), be subject to a fee 
established under subsection (c)(3). 
‘‘(B) EXCEPTION FOR REQUIRED SUBMIS-
SIONS.—A DTC advertisement that is required 
to be submitted to the Secretary prior to initial 
public dissemination is not subject to a fee 
under subparagraph (A) unless the sponsor des-
ignates the submission as a submission for advi-
sory review. 
‘‘(C) NOTICE TO SECRETARY OF NUMBER 
OF ADVERTISEMENTS.—Not later than June 1 
of each fiscal year, the Secretary shall publish 
a notice in the Federal Register requesting any 
person to notify the Secretary within 30 days of 
the number of DTC advertisements the person 
intends to submit for advisory review in the 
next fiscal year. Notwithstanding the preceding 
sentence, for fiscal year 2008, the Secretary 
shall publish such a notice in the Federal Reg-
ister not later than 30 days after the date of 
the enactment of the Food and Drug Adminis-
tration Amendments Act of 2007. 
‘‘(D) PAYMENT.— 
‘‘(i) IN GENERAL.—The fee required 
by subparagraph (A) (referred to in this
section as ‘an advisory review fee’) shall be 
due not later than October 1 of the fiscal 
year in which the DTC advertisement in-
volved is intended to be submitted for advi-
sory review, subject to subparagraph 
(F)(i). Notwithstanding the preceding sen-
tence, the advisory review fee for any DTC 
advertisement that is intended to be sub-
mitted for advisory review during fiscal 
year 2008 shall be due not later than 120 
days after the date of the enactment of the 
Food and Drug Administration Amend-
ments of 2007 or an earlier date as speci-
fied by the Secretary. 
‘‘(ii) EFFECT OF SUBMISSION.—Noti-
fication of the Secretary under subpara-
graph (C) of the number of DTC adver-
tisements a person intends to submit for 
advisory review is a legally binding com-
mitment by that person to pay the annual 
advisory review fee for that number of sub-
missions on or before October 1 of the fis-
cal year in which the advertisement is in-
tended to be submitted. Notwithstanding 
the preceding sentence, the commitment
shall be a legally binding commitment by 
that person to pay the annual advisory re-
view fee for that number of submissions 
for fiscal year 2008 by the date specified 
in clause (i). 
‘‘(iii) NOTICE REGARDING CARRYOVER 
SUBMISSIONS.—In making a notification 
under subparagraph (C), the person in-
volved shall in addition notify the Sec-
retary if under subparagraph (F)(i) the 
person intends to submit a DTC advertise-
ment for which the advisory review fee has 
already been paid. If the person does not 
so notify the Secretary, each DTC adver-
tisement submitted by the person for advi-
sory review in the fiscal year involved shall 
be subject to the advisory review fee. 
‘‘(E) MODIFICATION OF ADVISORY REVIEW 
FEE.— 
‘‘(i) LATE PAYMENT.—If a person has 
submitted a notification under subpara-
graph (C) with respect to a fiscal year and 
has not paid all advisory review fees due 
under subparagraph (D) not later than 
November 1 of such fiscal year (or, in the
case of such a notification submitted with 
respect to fiscal year 2008, not later than 
150 days after the date of the enactment 
of the Food and Drug Administration 
Amendments Act of 2007 or an earlier 
date specified by the Secretary), the fees 
shall be regarded as late and an increase 
in the amount of fees applies in accordance 
with this clause, notwithstanding any other 
provision of this section. For such person, 
all advisory review fees for such fiscal year 
shall be due and payable 20 days before 
any direct-to-consumer advertisement is 
submitted to the Secretary for advisory re-
view, and each such fee shall be equal to 
150 percent of the fee that otherwise 
would have applied pursuant to subsection 
(c)(3). 
‘‘(ii) EXCEEDING
IDENTIFIED
NUM-
BER OF SUBMISSIONS.—If a person sub-
mits a number of DTC advertisements for 
advisory review in a fiscal year that ex-
ceeds the number identified by the person 
under subparagraph (C), an increase in the 
amount of fees applies under this clause
for each submission in excess of such num-
ber, notwithstanding any other provision of 
this section. For each such DTC advertise-
ment, the advisory review fee shall be due 
and payable 20 days before the advertise-
ment is submitted to the Secretary, and 
the fee shall be equal to 150 percent of the 
fee that otherwise would have applied pur-
suant to subsection (c)(3). 
‘‘(F) LIMITS.— 
‘‘(i) SUBMISSIONS.—For each advi-
sory review fee paid by a person for a fis-
cal year, the person is entitled to accept-
ance for advisory review by the Secretary 
of one DTC advertisement and acceptance 
of one resubmission for advisory review of 
the same advertisement. The advertisement 
shall be submitted for review in the fiscal 
year for which the fee was assessed, except 
that a person may carry over not more 
than one paid advisory review submission 
to the next fiscal year. Resubmissions may 
be submitted without regard to the fiscal 
year of the initial advisory review submis-
sion.
‘‘(ii) NO REFUNDS.—Except as pro-
vided by subsections (d)(4) and (f), fees 
paid under this section shall not be re-
funded. 
‘‘(iii) NO WAIVERS, EXEMPTIONS, OR 
REDUCTIONS.—The Secretary shall not 
grant a waiver, exemption, or reduction of 
any fees due or payable under this section. 
‘‘(iv) RIGHT
TO
ADVISORY
REVIEW 
NOT TRANSFERABLE.—The right to an ad-
visory review under this paragraph is not 
transferable, except to a successor in inter-
est. 
‘‘(2) OPERATING RESERVE FEE.— 
‘‘(A) IN GENERAL.—Each person that on 
or after October 1, 2007, is assessed an advi-
sory review fee under paragraph (1) shall be 
subject to fee established under subsection 
(d)(2) (referred to in this section as an ‘oper-
ating reserve fee’) for the first fiscal year in 
which an advisory review fee is assessed to such 
person. The person is not subject to an oper-
ating reserve fee for any other fiscal year.
‘‘(B) PAYMENT.—Except as provided in 
subparagraph (C), the operating reserve fee 
shall be due no later than— 
‘‘(i) October 1 of the first fiscal year 
in which the person is required to pay an 
advisory review fee under paragraph (1); 
or 
‘‘(ii) for fiscal year 2008, 120 days 
after the date of the enactment of the 
Food and Drug Administration Amend-
ments Act of 2007 or an earlier date speci-
fied by the Secretary. 
‘‘(C) LATE NOTICE OF SUBMISSION.—If, in 
the first fiscal year of a person’s participation 
in the program under this section, that person 
submits any DTC advertisements for advisory 
review that are in excess of the number identi-
fied by that person in response to the Federal 
Register 
notice 
described 
in 
subsection 
(a)(1)(C), that person shall pay an operating 
reserve fee for each of those advisory reviews 
equal to the advisory review fee for each sub-
mission established under paragraph (1)(E)(ii). 
Fees required by this subparagraph shall be in 
addition to any fees required by subparagraph
(A). Fees under this subparagraph shall be due 
20 days before any DTC advertisement is sub-
mitted by such person to the Secretary for advi-
sory review. 
‘‘(D) LATE PAYMENT.— 
‘‘(i) IN
GENERAL.—Notwithstanding 
subparagraph (B), and subject to clause 
(ii), an operating reserve fee shall be re-
garded as late if the person required to 
pay the fee has not paid the complete oper-
ating reserve fee by— 
‘‘(I) for fiscal year 2008, 150 
days after the date of the enactment 
of the Food and Drug Administration 
Amendments Act of 2007 or an ear-
lier date specified by the Secretary; or 
‘‘(II) in any subsequent year, No-
vember 1. 
‘‘(ii) 
COMPLETE
PAYMENT.—The 
complete operating reserve fee shall be due 
and payable 20 days before any DTC ad-
vertisement is submitted by such person to 
the Secretary for advisory review. 
‘‘(iii) AMOUNT.—Notwithstanding any 
other provision of this section, an oper-
ating reserve fee that is regarded as late 
under this subparagraph shall be equal to 
150 percent of the operating reserve fee 
that otherwise would have applied pursu-
ant to subsection (d). 
‘‘(b) ADVISORY REVIEW FEE REVENUE AMOUNTS.— 
Fees under subsection (a)(1) shall be established to gen-
erate revenue amounts of $6,250,000 for each of fiscal 
years 2008 through 2012, as adjusted pursuant to sub-
sections (c) and (g)(4). 
‘‘(c) ADJUSTMENTS.— 
‘‘(1) 
INFLATION
ADJUSTMENT.—Beginning 
with fiscal year 2009, the revenues established in 
subsection (b) shall be adjusted by the Secretary by 
notice, published in the Federal Register, for a fiscal 
year to reflect the greater of— 
‘‘(A) the total percentage change that oc-
curred in the Consumer Price Index for all 
urban consumers (all items; U.S. city average), 
for the 12-month period ending June 30 pre-
ceding the fiscal year for which fees are being 
established; 
‘‘(B) the total percentage change for the 
previous fiscal year in basic pay under the Gen-
eral Schedule in accordance with section 5332
‘‘(ii) the Center for Biologics Evalua-
tion and Research, Advertising and Pro-
motional Labeling Branch, Food and Drug 
Administration. 
‘‘(3) AUTHORIZATION
OF
APPROPRIATIONS.— 
For each of the fiscal years 2008 through 2012, 
there is authorized to be appropriated for fees under 
this section an amount equal to the total revenue 
amount determined under subsection (b) for the fis-
cal year, as adjusted pursuant to subsection (c) and 
paragraph (4) of this subsection, plus amounts col-
lected for the reserve fund under subsection (d). 
‘‘(4) OFFSET.—Any amount of fees collected 
for a fiscal year under this section that exceeds the 
amount of fees specified in appropriation Acts for 
such fiscal year shall be credited to the appropria-
tion account of the Food and Drug Administration 
as provided in paragraph (1), and shall be sub-
tracted from the amount of fees that would other-
wise be collected under this section pursuant to ap-
propriation Acts for a subsequent fiscal year. 
‘‘(h) DEFINITIONS.—For purposes of this section: 
‘‘(1) The term ‘advisory review’ means review-
ing and providing advisory comments on DTC adver-
tisements regarding compliance of a proposed adver-